Precigen (PGEN): Commercial Launch Success Validates Early Capital Raise Thesis Soumya Eswaran Mon, October 12, 2026 at 11:38 AM EDT 3 min read ^GSPC +0.03% PGEN -0.51% SPGI +1.20% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Patient Capital Management, based in Baltimore, released its third-quarter 2026 investor letter for the "Patient Opportunity Equity Strategy". The letter can be downloaded here. The Opportunity Equity Strategy outperformed the S&P 500 in the latest quarter, gaining 4.32% compared to 2.30%, and is up 14.93% year-to-date versus the index's 12.75%. The market shows resilience, despite rate increases presenting risks and opportunities. The current market is seen as part of a long bull run, especially since March 2009, with the S&P compounding at 16.9% per year. The AI revolution adds complexity, and investor skepticism persists amidst rising valuations, yet strong corporate earnings suggest potential. The focus remains on understanding price expectations and evaluating risks, particularly around AI durability and supply-demand for computing capacity. The portfolio is concentrated in top 10 holdings, suggesting a disciplined approach towards valuation and risk management amidst market volatility. Also, check the strategy's top five holdings to see its best picks in 2026.
In its Q3 2026 investor letter, Patient Opportunity Equity Strategy highlighted Precigen, Inc. (NASDAQ:PGEN). Precigen, Inc. (NASDAQ:PGEN) is a discovery and clinical-stage biopharmaceutical company focusing on developing gene and cell therapies in areas of immuno-oncology, autoimmune disorders, and infectious diseases. On October 09, 2026, Precigen, Inc. (NASDAQ:PGEN) closed at $7.81, with a $2.8 billion market capitalization. Precigen, Inc. (NASDAQ:PGEN) posted a ~86.84% YTD gain, trading within a 52-week range of $3.04 to $8.98.
Patient Opportunity Equity Strategy stated the following regarding Precigen, Inc. (NASDAQ:PGEN) in its Q3 2026 investor letter:
Precigen, Inc. (NASDAQ:PGEN) (PGEN $7.60) has been a huge homerun since we led their capital raise at the end of 2024. Since then, the stock is a 10-bagger. Gains have been driven by a successful launch of its first drug, Papzimeous, for the rare and devastating disease, recurrent respiratory papillomatosis, which is caused by HPV virus. Precigen has worked out fantastically, but success was never guaranteed. When we initially invested, we believed the enormous upside potential more than compensated for the downside risk. It only takes a few big winners to pay for many losers.
We met with management recently and continue to see significant upside potential. The underlying technology of Papzimeous, Adenoverse, was recently granted FDA platform designation. This eases approval requirements for other Adenoverse related treatments, such as for HPV cancers. Precigen will report trial results soon for head-and-neck and cervical cancer – we are expecting solid results. We also see significant potential in its CAR-T program. After its move, Precigen's stock price is $7.60, which doesn't yet fully reflect the value of Papzimeous, let alone the other pipeline assets."
Precigen, Inc. (NASDAQ:PGEN) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 27 hedge fund portfolios held Precigen, Inc. (NASDAQ:PGEN) at the end of the second quarter, which was 29 in the previous quarter. While we acknowledge the potential of Precigen, Inc. (NASDAQ:PGEN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
In earlier Precigen, Inc. (NASDAQ:PGEN) coverage we noted FDA recognition may streamline development, but unquantified savings and clinical trial demands leave ultimate benefits uncertain. In addition, please check out our hedge fund investor letters Q3 2026 page for more investor letters from hedge funds and other leading investors.
This article is originally published at Insider Monkey.
